NBPF member 5, pseudogeneGenealiases: DKFZp434D177-like · NBPF5
Q-omics provides the consensus-scored NBPF5P profile across patient tissues and cancer cell-line models. NBPF5P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NBPF5P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, NBPF5P RNA expression shows 6,381 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight LIHC, and BRCA as cancer lineages where NBPF5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF5P survival associations across molecular data types. NBPF5P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF5P RNA expression–survival associations across cancer types. High NBPF5P expression shows unfavorable associations in LIHC, COAD, CHOL, LGG and UCEC, but favorable associations in PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NBPF5P RNA expression.
This table summarizes NBPF5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF5P shows higher tumor expression in BRCA, LUSC and LUAD. The BRCA box plot shows higher NBPF5P RNA expression in tumor versus normal tissue (log2 FC = +0.098, t-test p = .003).
This table shows molecular features associated with NBPF5P in patient tissues and cancer cell lines. In patient samples, NBPF5P shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
